Video

Dr. Samuelson on Frontline Treatment and Subsequent Sequencing in Prostate Cancer

Scott Samuelson, MD, medical oncologist, Utah Cancer Specialists, on frontline treatment of patients with prostate cancer and subsequent sequencing.

Scott Samuelson, MD, medical oncologist, Utah Cancer Specialists, discusses frontline treatment of patients with prostate cancer and subsequent sequencing.

A lot of the decision depends on a patient’s performance status, says Samuelson. Whether or not they are a candidate for chemotherapy is a big factor as well. Considering a patient’s eligibility for chemotherapy is very important as it is a very effective therapeutic agent. However, Samuelson states that abiraterone acetate (Zytiga) and enzalutamide (Xtandi) are also great options. For a lot of patients, the decision comes down to cost.

Samuelson takes care of a number of patients who live several hours from the clinic. Oral agents tend to be preferable for these patients. The costs of some of the oral agents, though usually not prohibitive, do pose an additional challenge for some patients. These patients may prefer an intravenous agent that tends to be covered better by insurance, says Samuelson.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD